Evidence map›Paper›PMID 25310407›Full record

ArticleThe Journal of investigative dermatology2015

Deletion of the major bullous pemphigoid epitope region of collagen XVII induces blistering, autoimmunization, and itching in mice.

Tiina Hurskainen, Nina Kokkonen, Raija Sormunen, Joanna Jackow, Stefanie Löffek, Raija Soininen, Claus-Werner Franzke, Leena Bruckner-Tuderman, Kaisa Tasanen

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. BP180/Collagen XVII: A Molecular View.International journal of molecular sciences · 2021
    Review
  8. Article
  9. Review
  10. Article
  11. BP180 dysfunction triggers spontaneous skin inflammation in mice.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  12. Review
  13. Review
  14. Eosinophils in Autoimmune Diseases.Frontiers in immunology · 2017
    Review
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Tiina HurskainenDepartment of Dermatology, University of Oulu, Oulu, Finland; Medical Research Center Oulu (MRC Oulu), Oulu University Hospital, Oulu, Finland.
Nina KokkonenDepartment of Dermatology, University of Oulu, Oulu, Finland; Medical Research Center Oulu (MRC Oulu), Oulu University Hospital, Oulu, Finland.
Raija SormunenBiocenter Oulu, University of Oulu, Oulu, Finland; Department of Pathology, University of Oulu, Finland and Oulu University Hospital, Oulu, Finland.
Joanna JackowLaboratory of Genetic Skin Diseases, Inserm UMR1163 and Imagine Institute of Genetic Diseases, Paris, France.
Stefanie LöffekDepartment of Dermatology, University Medical Center Freiburg and Freiburg Institute of Advanced Studies, University of Freiburg, Freiburg, Germany.
Raija SoininenBiocenter Oulu, University of Oulu, Oulu, Finland; Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland.
Claus-Werner FranzkeDepartment of Dermatology, University Medical Center Freiburg and Freiburg Institute of Advanced Studies, University of Freiburg, Freiburg, Germany.
Leena Bruckner-TudermanDepartment of Dermatology, University Medical Center Freiburg and Freiburg Institute of Advanced Studies, University of Freiburg, Freiburg, Germany.
Kaisa TasanenDepartment of Dermatology, University of Oulu, Oulu, Finland; Medical Research Center Oulu (MRC Oulu), Oulu University Hospital, Oulu, Finland. Electronic address: kaisa.tasanen@oulu.fi.
Oulu University Hospital · FIUniversity of Freiburg · DEInserm · FRUniversity Medical Center Freiburg · DEUniversity of Oulu · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering skin disease with a characteristic of pruritus and blistering. BP patients carry inflammation-triggering autoantibodies against the collagen XVII (ColXVII, also known as BP180) juxtamembraneous extracellular noncollagenous 16A (NC16A) domain involved in ectodomain shedding. Deletion of the corresponding NC14A region in a genetically modified mouse model (ΔNC14A) decreased the amount of ColXVII in skin, but it did not prevent ectodomain shedding. Newborn ΔNC14A mice had no macroscopic phenotypic changes. However, subepidermal microblisters, rudimentary hemidesmosomes, and loose basement membrane zone were observed by microscopy. ΔNC14A mice grow normally, but at around 3 months of age they start to scratch themselves and develop crusted erosions. Furthermore, perilesional eosinophilic infiltrations in the skin, eosinophilia, and elevated serum IgE levels are detected. Despite the removal of the major BP epitope region, ΔNC14A mice developed IgG and IgA autoantibodies with subepidermal reactivity, indicating autoimmunization against a dermo-epidermal junction component. Moreover, IgG autoantibodies recognized a 180-kDa keratinocyte protein, which was sensitive to collagenase digestion. We show here that ΔNC14A mice provide a highly reproducible BP-related mouse model with spontaneous breakage of self-tolerance and development of autoantibodies.

Indexed as

Gene DeletionAnimalsAutoantibodiesAutoantigensAutoimmunityBlisterCells, CulturedCollagen Type XVIIDisease Models, AnimalEpitopesKeratinocytesMiceMice, Inbred C57BLMice, KnockoutNon-Fibrillar CollagensPemphigoid, BullousAutoantibodiesAutoantigensCollagen Type XVIIEpitopesNon-Fibrillar Collagens

Identifiers

PMID25310407
OpenAlexW2131166358

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.